Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03173092 · ClinicalTrials.gov registry record · Phase 4

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

A Phase 4 study of Multiple Myeloma, sponsored by Takeda.

Active
Registry status
Phase 4
Development phase
141
Enrollment target
20
Study locations

NCT03173092 is a Phase 4 study of Multiple Myeloma that is active but no longer recruiting, run by Takeda. The registered enrollment target is 141 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03173092, a Phase 4 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Takeda.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
141 participants
Enrollment target
20
Study locations

Study Summary

The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 years in participants who previously received a bortezomib-based induction regimen. The study will enroll approximately 160 participants, who are enrolled after completing 3 cycles of chemotherapy (Bortezomib-Based Induction Regimen). They are then treated with Ixazomib in addition to lenalidomide and dexamethasone.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Ixazomib

Study Locations (20)

California

  • Los Angeles Cancer Network/(Formerly -Pacific Cancer Medical Center) - Anaheim
  • Compassionate Care Research Group, Inc. - Fountain Valley
  • Innovative Clinical Research - Santa Ana

Texas

  • Texas Oncology- Presbyterian Cancer Center Dallas - Dallas
  • Texas Oncology-San Antonio Northwest - San Antonio
  • Millennium Physicians Association - Shenandoah

Maryland

  • Saint Agnes Hospital - Baltimore
  • American Oncology Partners of Maryland P.A - Bethesda

Missouri

  • Central Care Cancer Center - Bolivar
  • Kansas City Veterans Affairs Medical Center - Kansas City

Arizona

  • Arizona Oncology Associates - Tucson

Colorado

  • US Oncology Research - Colorado Springs

Florida

  • Woodlands Medical Specialists- Pensacola - Pensacola

Georgia

  • Winship Cancer Institute of Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2017-11-13
Est. Completion 2026-11-30
Phase Phase 4

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03173092

The ClinicalTrials.gov registry entry for NCT03173092 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (74% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT03173092 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Texas, Maryland.

Frequently Asked Questions

What is clinical trial NCT03173092 about?

NCT03173092 is a clinical study titled "A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)". The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 years in participants who previously received a bortezomib-based induction regimen. The study will enroll approximately 160 participants, who are enroll...

What is the current status of trial NCT03173092?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 141 participants. The study started on 2017-11-13. Estimated completion is 2026-11-30.

What conditions does trial NCT03173092 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT03173092?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Ixazomib (DRUG).

Who is sponsoring clinical trial NCT03173092?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03173092 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.